Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer

NCT05600582 is registered in ClinicalTrials.gov with Codagenix, Inc as lead sponsor.

NCT NCT05600582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05600582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer
Lead sponsor
Codagenix, Inc
Phase
Phase 1
Overall status
Withdrawn
Start date
January 15, 2023
Completion date
January 30, 2025
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, neoplasm metastasis